XTAI
6541
Market cap338mUSD
Jun 18, Last price
40.45TWD
1D
0.00%
1Q
-5.05%
Jan 2017
-73.59%
IPO
-61.65%
Name
Tanvex BioPharma Inc
Chart & Performance
P/E
—
P/S
309.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.29%
Rev. gr., 5y
%
Revenues
35m
-43.53%
Net income
-1.38b
L-35.35%
CFO
-1.15b
L-19.75%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||